Disposition of roxithromycin in patients with normal and severely impaired renal function
- 1 March 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (3) , 385-389
- https://doi.org/10.1128/aac.34.3.385
Abstract
The disposition of roxithromycin, an investigational macrolide antibiotic, was evaluated in 20 subjects, 10 with normal renal function (creatinine clearance [CLCR] of 116 +/- 17 ml/min [mean +/- standard deviation]) and 10 with severely impaired renal function (CLCR of 10.2 +/- 2.6 ml/min) after a single 300-mg oral dose. Plasma concentration-time data were analyzed in terms of a one- or two-compartment oral absorption model utilizing nonlinear regression analysis. The terminal elimination half-life was significantly prolonged in the group with severely impaired renal function (15.5 +/- 4.7 h) compared with that of the group with normal renal function (7.9 +/- 2.5 h). Apparent total body clearance was significantly reduced in the renally impaired (25.3 +/- 10.5 ml/min) in relation to the group with normal renal function (48.8 +/- 11.1 ml/min). The first-order absorption rate constants and apparent volumes of distribution did not differ between the two groups. These data indicate that the disposition of roxithromycin is significantly delayed in subjects with CLCRs of less than 15 ml/min and suggest that the roxithromycin dosing interval be doubled for these patients.This publication has 13 references indexed in Scilit:
- Pharmacokinetics and tissue penetration of roxithromycin after multiple dosingAntimicrobial Agents and Chemotherapy, 1987
- CHANGES IN ERYTHROMYCIN PHARMACOKINETICS INDUCED BY RENAL-FAILURE1987
- Roxithromycin: a pharmacokinetic review of a macrolideJournal of Antimicrobial Chemotherapy, 1987
- Renal Disease and Drug Metabolism: An OverviewAmerican Journal of Kidney Diseases, 1986
- Cefotaxime and desacetyl cefotaxime kinetics in renal impairmentClinical Pharmacology & Therapeutics, 1985
- Protein Binding of Disopyramide and Elevated Alpha-1-Acid Glycoprotein Concentrations in Serum Obtained from Dialysis Patients and Renal Transplant RecipientsAmerican Journal of Nephrology, 1985
- In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugsAntimicrobial Agents and Chemotherapy, 1983
- Pharmacokinetics of Intravenous ErythromycinJournal of Pharmaceutical Sciences, 1978
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978